-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Neuroendocrine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Neuroendocrine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Neuroendocrine Cancer Drug Details: Tivozanib Hydrochloride (Fotivda) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Transitional Cell Cancer (Urothelial Cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CDX-301 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-301 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-301 in Metastatic Breast Cancer Drug Details: CDX-301 is under development...
-
Product Insights
Peritoneal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Peritoneal Tumor - Drugs In Development, 2023’, provides an overview of the Peritoneal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peritoneal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pancreatic Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Pancreatic Tumor - Drugs In Development, 2023’, provides an overview of the Pancreatic Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatic Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2023’, provides an overview of the Cancer Anorexia-Cachexia Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Oropharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Oropharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Oropharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gallbladder Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Gallbladder Cancer - Drugs In Development, 2023’, provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...